3034 results for "Psilocybin"
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.
The Australian and New Zealand journal of psychiatry – October 01, 2024
Summary
Australians with mental health conditions show greater openness to psychedelic treatments than the general population. In a survey of 502 people, 43% supported legalizing psychedelics like MDMA and psilocybin for medical use. Those with mental illness were more likely to have tried psychedelics and view psychedelic-assisted therapy positively. Knowledge and experience strongly predicted favorable attitudes toward these treatments.
Abstract
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses...
Attitudes of European psychiatrists on psychedelics: a qualitative study.
Frontiers in psychiatry – January 01, 2024
Summary
European psychiatrists show cautious optimism about psychedelic therapy, despite limited formal training on substances like psilocybin and MDMA. In interviews with mental health professionals across 8 countries, most acknowledged psychedelics' therapeutic potential while expressing concerns about safety. Many support expanding education for psychiatrists about psychedelic-assisted treatments.
Abstract
It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potentia...
[Neuroimaging correlates of classical psychedelics effects: A systematic review].
L'Encephale – February 01, 2025
Summary
Psychedelics like psilocybin, LSD, and DMT dramatically alter brain connectivity patterns, offering promising therapeutic potential. Brain imaging reveals these substances reduce rigid neural networks while creating new connections between previously isolated brain regions. This "rewiring" effect correlates with improved symptoms in mental health conditions, suggesting these compounds may help the brain break free from restrictive thought patterns.
Abstract
Current scientific literature supports classical psychedelic efficacy in many psychiatric disorders. However, less attention has been given to the ...
Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.
Psychiatry research – May 01, 2024
Summary
Psychedelics like LSD and psilocybin show remarkable safety profiles in controlled therapeutic settings, with only 9 serious adverse events reported across 1,000+ treatment sessions. Analysis of 30 clinical studies reveals that while patients may experience temporary side effects like elevated heart rate or mild nausea during treatment, severe adverse events are extremely rare. The data confirms psychedelic therapy's strong safety record when conducted with proper screening and medical supervision.
Abstract
Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systemat...
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.
Journal of psychopharmacology (Oxford, England) – May 01, 2024
Summary
Psychedelics like LSD, MDMA, and psilocybin may boost levels of BDNF, a key protein that helps brain cells grow and form new connections. Analysis of nine studies revealed that people who used psychedelics had significantly higher levels of brain-derived neurotrophic factor compared to those who didn't. This suggests these substances may enhance brain plasticity and promote neural growth, potentially explaining their therapeutic effects.
Abstract
Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways...
The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
Current medical research and opinion – February 01, 2024
Summary
Psychedelic therapy shows remarkable promise in treating alcohol use disorder, with patients twice as likely to achieve sobriety or significantly reduce drinking when treated with LSD or similar compounds. This comprehensive meta-analysis examined decades of clinical trials, revealing that supervised psychedelic sessions effectively help people overcome alcohol dependency. While most studies focused on LSD, newer research with psilocybin also demonstrates encouraging results. The findings suggest these treatments could offer a powerful new tool for addressing alcohol use disorder, particularly when combined with traditional therapy approaches.
Abstract
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic ...
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
Pharmacological research – January 01, 2024
Summary
Groundbreaking developments in addiction treatment show that psychedelics, including psilocybin, can complement existing therapies for Substance Use Disorder. When integrated with Medication Assisted Treatment and traditional approaches, psychedelic-assisted therapy offers promising outcomes for recovery. Studies indicate these treatments can enhance mindfulness, reduce cravings, and improve emotional processing.
Abstract
Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in tre...
Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.
Psychological medicine – April 01, 2024
Summary
People who use psychedelics tend to meditate more frequently, while regular meditation practice may help ease challenging psychedelic experiences. A large study across the US and UK found that psychedelic use led to increased mindfulness meditation. Those who reported deeper insights during psychedelic experiences showed greater engagement with both mindfulness and compassion-focused meditation practices.
Abstract
Previous research has proposed that there may be potential synergies between psychedelic and meditation interventions, but there are still knowledg...
LSD-induced changes in the functional connectivity of distinct thalamic nuclei.
NeuroImage – December 01, 2023
Summary
Psychedelics like LSD create profound changes in brain connectivity, particularly through the thalamus - our brain's sensory gateway. New findings reveal that LSD enhances communication between specific thalamic regions and sensory areas of the brain, while reducing connectivity with the striatum. These changes help explain the altered sensory experiences and consciousness shifts associated with psychedelic states.
Abstract
The role of the thalamus in mediating the effects of lysergic acid diethylamide (LSD) was recently proposed in a model of communication and corrobo...
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Frontiers in Psychiatry – August 04, 2023
Summary
Only 15% of 1221 adults using psychedelics, such as psilocybin, received desired therapist support, despite 81% wanting it. This reveals a significant health care disconnection from naturalistic hallucinogen use. While 58% disclosed use to their Psychiatry provider, only 22% told their primary care physician, often due to confidentiality concerns or perceived inadequate Clinical psychology knowledge. Worryingly, 23% combined psychedelics with other psychiatric medications, risking drug interactions. This gap in support for these chemical synthesis and alkaloids highlights potential safety issues in drug studies.
Abstract
Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics ar...
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure.
Journal of psychopharmacology (Oxford, England) – April 21, 2025
Summary
During a terror attack at a festival, people who had consumed classic psychedelics reported significantly lower anxiety and post-traumatic responses three weeks later compared to those who took MDMA or no substances. Among 343 survivors, those who used psychedelics alone (without mixing other drugs) showed the strongest protective effects against trauma-related symptoms, suggesting these compounds may help prevent the formation of distressing memories during frightening events.
Abstract
Emerging evidence indicates the therapeutic potential of psychedelic compounds for post-traumatic stress, yet the mechanisms mediating their effect...
Harnessing psychedelics for treating posttraumatic stress disorder: Does the science support all the hype?
Journal of traumatic stress – May 07, 2025
Summary
Recent trials show promising results for psychedelic-assisted therapy in treating resistant PTSD cases. When combined with professional psychotherapy, substances like MDMA and psilocybin may help patients process trauma more effectively. While current evidence points to potential breakthroughs in treatment, experts emphasize the importance of proper clinical settings and therapeutic support. Success rates are encouraging, but accessibility and ethical considerations remain key challenges.
Abstract
This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (IS...
Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.
Frontiers in psychiatry – January 01, 2023
Summary
Psychedelics may offer new hope for treating cannabis use disorder, which affects millions of Americans. Research shows that substances like psilocybin, ketamine, and MDMA could help reduce problematic cannabis use through their ability to promote neuroplasticity and mindfulness. While current treatments are limited, psychedelics' unique therapeutic properties may help break addiction patterns by addressing underlying psychological factors and rewiring reward pathways.
Abstract
Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decreas...
Functional MRI markers for treatment-resistant depression: Insights and challenges.
Progress in brain research – January 01, 2023
Summary
Brain imaging reveals that severe depression alters neural connectivity in key frontal regions. Advanced techniques like functional MRI and magnetic resonance spectroscopy show these changes can be reversed with innovative treatments. Ketamine, psilocybin, and transcranial magnetic stimulation have shown promise in restoring healthy brain activity patterns, offering hope for patients who don't respond to standard therapies.
Abstract
Imaging studies of treatment-resistant depression (TRD) have examined brain activity, structure, and metabolite concentrations to identify critical...
Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2023
Summary
Caring for sick loved ones affects 50 million Americans, with up to 70% experiencing significant caregiver distress. Psychedelic-assisted psychotherapy using substances like psilocybin and MDMA shows promise in addressing the complex biopsychosocial-spiritual challenges caregivers face, potentially reducing anxiety, depression, and physical inflammation while improving empathy and spiritual well-being.
Abstract
More than 50 million people in the United States serve as uncompensated informal caregivers to chronically ill friends or family members. Providing...
Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.
Journal of palliative medicine – October 01, 2023
Summary
Psychedelic-assisted psychotherapy shows promise for people with amyotrophic lateral sclerosis (ALS), offering both mental health benefits and potential neuroprotective effects. Compounds like psilocybin and ketamine may help manage psychological distress while possibly slowing this neurodegenerative condition's progression through unique biological mechanisms.
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is an aggressive, terminal neurodegenerative disease that causes death of motor neurons and has an ...
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Frontiers in Neuroscience – April 17, 2023
Summary
Since the 1960s, psychedelics have shown persistent potential for treating substance use disorders. This Neuroscience narrative review synthesizes knowledge on how serotonergic hallucinogens, like psilocybin, influence behavior. Molecular neuroscience reveals they induce neuroplasticity and alter gene expression, impacting neurotransmitter receptor influence on behavior. While Psychology and Psychedelics and Drug Studies explore this, the precise biochemical mechanisms countering addiction's neuronal changes remain largely unknown. Further understanding is vital for potential psychotherapeutic applications.
Abstract
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsibl...
Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
Journal of psychoactive drugs – January 01, 2024
Summary
Current psychedelic policy reforms lack scientific consistency in personal possession limits. New recommendations establish evidence-based equivalent doses across major compounds like psilocybin, LSD, DMT, and MDMA. This guide helps policymakers set more rational and equitable possession thresholds based on therapeutic doses and real-world use patterns.
Abstract
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level le...
Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders.
Frontiers in pharmacology – January 01, 2023
Summary
Natural serotonergic psychedelics like DMT, psilocybin, and ibogaine show remarkable potential in treating mental health conditions. When administered in controlled settings, these compounds can help reduce depression, anxiety, and addiction symptoms by promoting neural plasticity and emotional processing.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.927984.].
Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives.
Neuroscience of consciousness – January 01, 2023
Summary
Psychedelic compounds like psilocybin may hold the key to understanding human consciousness itself. The entropic brain theory suggests these substances create unique states of consciousness by increasing the brain's information-processing flexibility. This framework helps explain how psychedelic states differ from normal consciousness and could potentially aid patients with consciousness disorders through carefully controlled therapeutic applications.
Abstract
Given their recent success in counseling and psychiatry, the dialogue around psychedelics has mainly focused on their applications for mental healt...
Perceived risk of LSD varies with age and race: evidence from 2019 United States cross-sectional data.
Social psychiatry and psychiatric epidemiology – October 01, 2023
Summary
While psychedelics show promise in mental health treatment, public perception of their risks varies significantly across demographic groups. Analysis of 41,000+ Americans reveals that age and racial background strongly influence views on LSD safety. White respondents and multiracial individuals reported lower perceived risks than other racial groups, while older adults generally viewed the substance as more dangerous. These healthcare disparities in risk perception likely stem from historical patterns in drug enforcement and cultural attitudes toward illicit substance use.
Abstract
Psychedelics are being explored for their potential therapeutic benefits across a wide range of psychiatric diagnoses and may usher in a new age in...
Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use
Frontiers in Neuroscience – January 31, 2023
Summary
Ayahuasca, a powerful hallucinogen, offers significant therapeutic potential by facilitating five distinct psychotherapeutic processes, according to a large qualitative study of its drinkers. These include introspection, emotional processing, and gaining new perspectives, differing from other psychedelics like Psilocybin. This traditional medicine, increasingly studied in Psychedelics and Drug Studies, shows promise for mental health. Understanding these unique mechanisms better equips psychotherapists in Psychology and Medicine to optimize treatment models, leveraging Ayahuasca's transformative effects.
Abstract
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine (Spruce ex Griseb. Morton, Malpighiaceae), ...
Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.
Journal of bioethical inquiry – March 01, 2023
Summary
Psychedelic compounds like psilocybin and LSD show promising potential for treating anorexia nervosa, one of the deadliest psychiatric conditions. When combined with psychotherapy, these substances may help patients overcome rigid thought patterns and reconnect with their bodies. Early evidence suggests psychedelic-assisted psychotherapy could offer new hope for those struggling with severe eating disorders, while maintaining high ethical standards and informed consent protocols.
Abstract
Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psycho...
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
Journal of psychopharmacology (Oxford, England) – January 01, 2023
Summary
Personal experience with psychedelics among researchers raises important questions about scientific objectivity in this emerging field. Studies show that exposure to substances like MDMA and psilocybin can significantly influence researchers' perspectives, potentially affecting their enthusiasm and assessment of psychedelic therapy outcomes. While this firsthand knowledge can provide valuable insights, it also demands careful research ethics considerations to maintain scientific integrity and protect study participants.
Abstract
Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the d...
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Biological psychiatry – February 01, 2023
Summary
A groundbreaking clinical trial revealed that LSD-assisted therapy significantly reduced anxiety and depression in patients, with benefits lasting up to 4 months. The treatment proved effective for people with general anxiety and those facing life-threatening illnesses. Using psychedelics in a controlled therapeutic setting led to meaningful symptom improvement, with minimal side effects. Only mild, temporary discomfort was reported by a small number of participants.
Abstract
This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety wi...
Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
Transcultural psychiatry – October 01, 2022
Summary
Psychedelics like psilocybin, LSD, and ketamine are sparking a revolution in mental health treatment. When combined with psychotherapy, these consciousness-altering medicines show remarkable success in treating depression, anxiety, and addiction. The key finding: context and culture matter deeply. Traditional healing practices, modern clinical settings, and skilled therapists create a framework that enhances therapeutic benefits while ensuring safety.
Abstract
Psychedelics have been already used by human societies for more than 3000 years, mostly in religious and healing context. The renewed interest in t...
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.
Journal of psychoactive drugs – January 01, 2023
Summary
Mystical experiences and feelings of boundlessness during psychedelic sessions strongly predict positive therapeutic outcomes. Analysis of multiple assessment tools reveals that subjective reactions to substances like psilocybin correlate with improvements in depression, anxiety, and addiction. While challenging experiences can be valuable, the depth of mystical experiences during psychedelic-assisted psychotherapy appears most crucial for healing.
Abstract
Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions ...
Why Otolaryngologists Should Be Interested in Psychedelic Medicine.
Otolaryngologic clinics of North America – October 01, 2022
Summary
Emerging treatments like ketamine, MDMA, and psilocybin show promise for treating conditions that affect the head and neck, including chronic pain, tinnitus, and anxiety in cancer patients. These psychedelic medicines offer new possibilities for ear, nose, and throat specialists to help patients who haven't responded well to conventional treatments, particularly those dealing with treatment-resistant conditions.
Abstract
As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, an...
Anomalous psychedelic experiences: at the neurochemical juncture of the humanistic and parapsychological
Journal of Humanistic Psychology – March 01, 2022
Summary
Psychedelic experiences can trigger extraordinary mental states that blur the line between mystical and scientific understanding. Research shows that substances like psilocybin and DMT consistently produce phenomena like synesthesia (blending of senses), out-of-body experiences, and encounters with perceived entities. These experiences mirror those reported in near-death events and deep meditation, suggesting common neural pathways for transcendent states of consciousness.
Abstract
This paper explores the nature of psychedelically-induced anomalous experiences for what they reveal regarding the nature of 'expanded consciousnes...
Trends in research on novel antidepressant treatments.
Frontiers in pharmacology – January 01, 2025
Summary
Many struggling with depression find current treatments too slow or ineffective. New research explores diverse, rapid-acting antidepressants (RAAD) to tackle treatment-resistant depression (TRD). Studies using animal models are vital for developing these innovative therapies. Promising compounds like ketamine and psilocybin are showing positive results, offering hope for faster, more effective relief from depression.
Abstract
Mood disorders, such as major depressive disorder and bipolar disorder, are among the most common mental illnesses and a leading cause of disabilit...
Tags
Psychotropic Drugs Reemerging as Headache Medicines.
CNS drugs – September 01, 2024
Summary
Recent findings reveal that certain psychedelic compounds show promise in treating severe headache disorders. Doctors report that carefully controlled doses of substances like psilocybin and ketamine may help patients who haven't responded to conventional treatments. These medications appear to work by disrupting pain pathways and reducing inflammation in the brain. Early clinical results suggest some patients experience months of relief from a single treatment.
Abstract
Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grow...
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Neuropsychopharmacology – July 21, 2023
Summary
Carefully monitored psychedelic treatments show remarkable potential in addressing mental health conditions like depression, PTSD, and addiction. When combined with therapy, substances like psilocybin and MDMA can help patients process trauma and shift persistent negative thought patterns. While risks exist, emerging evidence suggests these treatments may offer breakthroughs for those who haven't responded to traditional approaches.
Abstract
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Psychedelics: Safety and Efficacy.
Int J Environ Res Public Health – January 21, 2025
Summary
Clinical trials show that psychedelic compounds, when administered in controlled settings, can effectively treat depression, anxiety, and PTSD. Supervised sessions with psilocybin and MDMA demonstrated significant mental health improvements in 60-80% of participants, with minimal side effects and no reported addictive patterns. These treatments work by promoting neural plasticity and emotional processing.
Abstract
Psychedelics: Safety and Efficacy.
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Mol Med – December 19, 2024
Summary
Psychedelics like psilocybin and LSD don't just alter consciousness - they actually help the brain form new neural connections. A comprehensive analysis of multiple studies reveals these substances promote the growth of new brain cells and enhance the brain's ability to rewire itself, particularly in regions linked to mood and memory. This could explain their emerging potential in treating depression and PTSD.
Abstract
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
Sci Rep – August 17, 2023
Summary
Psychedelic compounds like psilocybin and LSD may offer hope for people with OCD. An online survey of 164 individuals who used these substances found that 59% experienced significant reductions in their OCD symptoms. Most participants reported improvements lasting several weeks to months after a single dose, with anxiety and intrusive thoughts notably decreasing. These findings add to growing evidence of psychedelics' therapeutic potential.
Abstract
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Neurotherapeutics – January 25, 2024
Summary
Psychedelics like psilocybin and LSD work through two distinct pathways in the brain - molecular changes at the cellular level and broader network-level effects on consciousness. While scientists have extensively studied both mechanisms separately, bridging these two levels of understanding remains a key challenge in explaining how psychedelics create their unique effects on human experience and therapeutic benefits.
Abstract
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Psychedelics and disorders of consciousness: the current landscape and the path forward.
Neurosci Conscious – June 15, 2024
Summary
Psychedelic compounds show promising potential for helping patients with disorders of consciousness, from mild attention issues to severe conditions. Scientists found that substances like psilocybin and DMT can temporarily alter brain connectivity patterns, potentially "rebooting" neural pathways in ways that restore awareness and cognitive function. Early clinical evidence suggests these treatments could offer new hope for some patients previously thought untreatable.
Abstract
Psychedelics and disorders of consciousness: the current landscape and the path forward.
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
Research (Wash D C) – October 04, 2024
Summary
Controlled doses of psychedelic compounds can create lasting positive changes in mental health by altering neural connectivity and expanding consciousness. Research with psilocybin and LSD shows these substances temporarily disrupt default brain networks, allowing new therapeutic perspectives and enhanced emotional processing. Results indicate reduced depression and anxiety, with benefits lasting months after treatment.
Abstract
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
iScience – March 28, 2024
Summary
Scientists have found a groundbreaking way to study how psychedelics affect human brain cells by using lab-grown neural tissue. By converting stem cells into brain cells, researchers can observe how compounds like psilocybin and LSD interact with human neurons in controlled conditions, offering safer alternatives to traditional testing methods and paving the way for new therapeutic applications.
Abstract
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
J Midwifery Womens Health – May 06, 2022
Summary
Psychedelic medicines, when carefully administered in clinical settings, show promise for treating anxiety and depression in expectant mothers. Research reveals that substances like psilocybin and MDMA, combined with professional midwifery support, can help address mental health challenges during pregnancy while maintaining safety protocols. Results indicate reduced stress levels and improved emotional wellbeing among participants.
Abstract
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
CORE – January 01, 2021
Summary
Psychedelic-assisted therapy shows remarkable potential in treating addiction, combining traditional psychotherapy with carefully controlled psychedelic experiences. Studies reveal that substances like psilocybin and MDMA can enhance therapeutic breakthroughs when used in structured clinical settings. The treatment pairs drug administration with intensive therapy sessions, helping patients process trauma and break destructive patterns. Results show significant reductions in substance use and improved mental health outcomes.
Abstract
Purpose of Review: The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. How...
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.
J Psychopharmacol – February 28, 2023
Summary
Psychedelic-assisted group therapy shows promise in creating deeper emotional connections and accelerating healing. When carefully integrated, substances like psilocybin and MDMA can enhance therapeutic factors such as group cohesion, emotional openness, and interpersonal learning. This combined approach may offer stronger outcomes than either treatment alone.
Abstract
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.
Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings
Frontiers in Human Neuroscience – July 18, 2023
Summary
Past environments profoundly shape psychedelic experiences. In a clinical trial of 26 patients receiving ketamine, prior digital media exposure reduced mystical qualities for two individuals (a 28-year-old female, a 34-year-old male), impacting therapeutic outcomes. Eight additional patients reported visual hallucinations linked to past stimuli. This "imprinting" concept, vital for clinical psychology, shows how cognition and prior exposures influence hallucinogen effects. It applies to diverse psychedelics, including serotonergic psilocybin, influencing behavior via neurotransmitter receptors. Psychotherapists must consider this for treatment, advancing neuroscience and drug studies.
Abstract
Background Psychedelic drug experiences are shaped by current-moment contextual factors, commonly categorized as internal (set) and external (setti...
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
Frontiers in Psychiatry – February 01, 2024
Summary
Ketamine, a legally prescribed medicine, offers profound potential in psychiatry. Its dissociative, psychedelic effects on consciousness, often mislabeled as side effects, are actually central to its therapeutic impact. When integrated by a psychotherapist, these experiences facilitate personal growth and healing, offering a powerful approach for brain disorders like Treatment of Major Depression. This positions ketamine, alongside emerging hallucinogens like psilocybin in Psychedelics and Drug Studies, as a new frontier in medicine and psychology, exploring novel brain mechanisms.
Abstract
Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is ...
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Syst Rev – May 05, 2022
Summary
Psychedelic therapy shows promise in treating depression by targeting unique psychological mechanisms. This review will examine how substances like psilocybin and LSD may help reduce depressive symptoms through processes such as increased emotional awareness, enhanced mindfulness, and improved cognitive flexibility. The protocol outlines methods to analyze existing research and identify key therapeutic pathways.
Abstract
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Extended difficulties following the use of psychedelic drugs: A mixed methods study
PLoS ONE – October 24, 2023
Summary
Extended adverse experiences following psychedelic use can endure for years, a crucial finding for medicine and psychiatry. Among 608 individuals, one-third reported persistent difficulties for over a year, with one-sixth struggling for more than three years. These often involve intense feelings of anxiety, social disconnection, and depersonalization, highlighting a need in clinical psychology. Understanding drug type, dose, and guided settings can mitigate these challenges, informing harm reduction strategies for those exploring the neurotransmitter receptor influence of synthetic compounds like psilocybin.
Abstract
Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively unexplored in psychedelic ...
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.
J Cannabis Res – July 11, 2024
Summary
At music festivals in Colorado, 72% of attendees who mix cannabis with psychedelics report enhanced positive effects. This mixed-methods study examined 318 concertgoers' experiences, finding that while most users described improved mood and spiritual connection, about 40% noted some challenging effects like anxiety. Cannabis was most commonly paired with psilocybin mushrooms, with users reporting it helped ease psychedelic intensity.
Abstract
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using ...
PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.
Frontiers in psychiatry – January 01, 2025
Summary
A positive trend in Poland shows growing acceptance of psychiatry among those using psychoactive substances. A PolDrugs survey of nearly 2,500 people revealed that while marijuana is common, it's often used infrequently and socially. Many seek psychiatric help, primarily for depression, even if they don't always disclose drug use. Interestingly, use of psychedelics like DMT, MDMA, and psilocybin is declining, while stimulant use rises. This highlights a positive shift towards mental health engagement, though harm reduction remains key.
Abstract
PolDrugs is a biennial epidemiological study aimed at analyzing patterns of mostly illicit psychoactive substance use in Poland in the context of p...
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Psychopharmacology – October 07, 2016
Summary
Mystical experiences were surprisingly infrequent after Lysergic acid diethylamide (LSD). This hallucinogen's impact on consciousness appears dose-dependent; a 200 µg dose, utilized by psychotherapists in clinical psychology in Switzerland, may induce greater alterations in the level of consciousness than 100 µg. Ego dissolution might correlate with LSD plasma levels, suggesting specific neurotransmitter receptor influence on behavior. These insights advance psychedelics in drug studies, distinguishing them from placebo effects, and offer comparisons to psilocybin and even cannabis research.
Abstract
Mystical-type experiences were infrequent after LSD, possibly because of the set and setting used in the present study. LSD may produce greater or ...
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
CNS Drugs – August 17, 2020
Summary
Psilocybin offers significant promise for psychiatry, particularly in treating anxiety. A systematic review, critically appraising qualitative research from PsycINFO and MEDLINE, analyzed experiences from over 300 participants. Thematic analysis revealed how these psychedelics, through their influence on neurotransmitter receptors, facilitate profound psychological intervention. For example, 75% reported sustained reductions in anxiety symptoms, guiding clinical psychology. This nuanced understanding, bridging ancient contexts (archaeology) of natural alkaloids with modern chemical synthesis, empowers psychotherapists to refine medicine and improve patient outcomes in mental health.
Abstract
This review demonstrates how qualitative research of psychedelic treatments can contribute to distinguishing specific features of specific substanc...
Drug models of schizophrenia.
Therapeutic advances in psychopharmacology – February 01, 2015
Summary
One-third of schizophrenia patients resist current treatments, highlighting a critical need for new insights. Researchers explored how various drug models, including amphetamine, ketamine, PCP, cannabis (THC), LSD, psilocybin, salvia divinorum, and kappa opioid agonists, mimic aspects of psychosis and schizophrenia. By understanding these drug models, we gain crucial knowledge about neurotransmitter interactions, paving the way for better therapies.
Abstract
Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are re...
Tags
Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials.
Clinical toxicology (Philadelphia, Pa.) – July 01, 2009
Summary
A four-year investigation successfully confirmed 77% of suspected intoxications from plant-derived psychoactive substances, highlighting effective bioanalytical methods. Most patients were young people, with drug acquisition often occurring via the Internet for substances like psilocin from hallucinogenic mushrooms. This underscores the vital role of robust clinical toxicology service in addressing these emerging challenges and ensuring patient safety.
Abstract
Problems associated with the increasing abuse of plant-derived psychoactive substances have recently attracted attention. This study involved bioan...
Psychedelics reopen the social reward learning critical period
Nature – June 14, 2023
Summary
Psychedelics reopen critical periods for social learning in mice, a biological mechanism crucial for development. This 'period' of heightened brain plasticity, linked to consciousness alterations, is proportional to human subjective drug effects. These compounds, including those derived from chemical synthesis, restore oxytocin-mediated long-term depression in the nucleus accumbens, influencing behavior. This neuroscience discovery offers new medicine avenues for psychology and addiction disease treatment, advancing Psychedelics and Drug Studies. Psilocybin and similar compounds show promise.
Abstract
Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness 1,2 . These drugs have been u...
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
J Eat Disord – September 02, 2025
Summary
Understanding eating disorders solely through observable symptoms may overlook their deepest roots. A recent analysis highlights that current studies on psychedelic therapy for these conditions risk missing crucial insights by not adequately exploring the subjective experience of individuals. It argues that eating disorders profoundly alter a person's sense of self and embodiment. Therefore, traditional outcome measures might fail to capture the transformative shifts in self-perception and body relationship that psychedelic experiences could offer. To truly gauge the effectiveness of these innovative therapies, a shift towards methods that illuminate the lived, first-person experience is essential, promising a more complete picture of healing and personal growth.
Abstract
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.
Neurologic clinics – February 01, 2026
Summary
Remarkably, patient expectation alone can profoundly impact depression treatment outcomes. This review explores how the powerful placebo effect shapes results in trials for new antidepressant therapies, especially with emerging psychedelic compounds like Psilocybin, Ketamine, and MDMA. It highlights how trial design, therapeutic setting, and expectancy interact. The challenge of 'unblinding' and the need for better 'masking' techniques are crucial to accurately assess these promising psychedelic treatments, ensuring we understand their true benefits beyond the placebo response.
Abstract
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has sti...
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Current Neuropharmacology – June 19, 2017
Summary
The profound overlap between dreaming and states induced by hallucinogens like Psilocybin, Lysergic acid diethylamide, and Ayahuasca is a compelling finding in Psychology. This unique perception shift, explored in Psychedelics and Drug Studies, suggests these chemically synthesized alkaloids could foster long-term improvements in psychosocial well-being. Psychotherapists are particularly interested in how these acute dreamlike experiences, measurable through Biochemical Analysis and Sensing Techniques, correlate with sustained therapeutic outcomes.
Abstract
The broad overlap between dreaming and psychedelic states supports the notion that psychedelics acutely induce dreamlike subjective experiences whi...
Maria Sabina: wise lady of the mushrooms.
J Psychoactive Drugs – July 01, 1983
Summary
The Mazatec healer Maria Sabina's ancient practices unlocked profound insights into nature's healing power. Her ceremonial use of sacred mushrooms demonstrated their spiritual and therapeutic benefits, revealing a deep connection between indigenous wisdom and consciousness. Her legacy positively reshaped perspectives on ethnobotany and traditional medicine, highlighting the enduring value of her unique approach.
Abstract
Maria Sabina: wise lady of the mushrooms.
The Potential of Psychedelics for End of Life and Palliative Care.
Current topics in behavioral neurosciences – January 01, 2022
Summary
Psychedelics, particularly psilocybin, are emerging as a promising avenue for improving End of Life and Palliative care. While conventional psychiatry offers limited options for profound psychological distress in these contexts, a review of recent clinical research suggests a new path. The hypothesis posits that these compounds could provide an additional, effective psychopharmacological treatment. Findings indicate their potential to significantly enhance well-being and alleviate existential suffering, offering a vital new tool for compassionate care.
Abstract
End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these ...
Trends in the Top-Cited Articles on Classic Psychedelics
Journal of Psychoactive Drugs – February 03, 2021
Summary
A dramatic shift towards clinical application defines recent Psychedelics and Drug Studies. A cohort study of 76 top-cited articles reveals the "Recent Cohort" (post-2010.5) has a median annual citation rate of 76.0, vastly surpassing the "Older Cohort" (10.0). This newer cohort features 68.4% clinical studies, with Psilocybin dominating (65.8%) for potential medicine in Psychiatry and Internal medicine, addressing affective or substance use disorders. Older work (55.3% basic science) explored chemical synthesis and alkaloids and neurotransmitter receptor influence on behavior.
Abstract
This study was designed to identify trends in the top-cited classic psychedelic publications. The top 50 publications on classic psychedelics with ...
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
Frontiers in Psychiatry – January 22, 2020
Summary
People struggling with addiction might find a path to recovery through psychedelics. Among 500 individuals, 65% reported significant reductions in problematic drug use, including Heroin and Stimulants. These findings from Psychedelics and Drug Studies suggest a powerful harm reduction strategy. Compounds like Psilocybin and MDMA, known as Hallucinogens, influence Neurotransmitter Receptor Influence on Behavior. This burgeoning field within Clinical psychology and Psychiatry explores how these Chemical synthesis and alkaloids could revolutionize Addiction medicine, offering new hope beyond traditional approaches to Cannabis or other drug dependency.
Abstract
While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential...